Research. Advocacy. Support.
We advance ovarian cancer research while supporting women and their families.
Register for OCRFA's Ovarian Cancer National Conference
Join us for an informative and transformative weekend of inspiration and hope, July 13-15 in Washington DC. Meet other survivors, patients and caregivers, hear from experts, and make lasting connections with others who have been touched by ovarian cancer.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
Many factors can increase or decrease a woman's risk of developing ovarian cancer.
- Family history of breast, ovarian or colon cancer
- Genetic mutations like BRCA
- Increased age
- Use of oral contraceptives
Know the Symptoms
- Difficulty Eating
- Pelvic / Abdominal Pain
- Urinary Frequency
If these symptoms occur for more than 2 weeks and these symptoms are new or unusual for you, see a gynecologist and ask about ovarian cancer. Research shows that seeing a gynecologic oncologist for surgery and treatment significantly improves outcomes.
Spring Advocacy Day
OCRFA and our amazing advocates brought #TealAction to Capitol Hill on March 6, highlighting the need for increased ovarian cancer research funding and support at the federal level. Together, we are the voice of the ovarian cancer community.
Join ovarian cancer survivors, caregivers, researchers and healthcare providers at OCRFA’s Ovarian Cancer National Conference – an informative and transformative weekend of hope, inspiration and fun. Get a front row seat at expert plenary and breakout sessions, from the newly-expanded Ask the Experts, to sessions on understanding PARP inhibitors, and sexual health after cancer. Learn… More
(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer. In this pilot trial, 25 patients with advanced epithelial recurrent ovarian cancer were either given the vaccine alone, with the chemotherapy drug bevacizumab, or a… More
(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy. The evidence that led to the FDA approving rucaparib comes from the phase 3 ARIEL3 clinical trial, which enrolled 564… More
OCRFA’s indoor cycling event comes to San Mateo on April 22, 2018. Ride for a cure for ovarian...April 22 @ 1:00 pm - 2:00 pm PDT
OCRFA’s indoor cycling event returns to Chicago on April 22, 2018. Ride with us to defeat ovar...April 22 @ 2:30 pm - 4:30 pm CDT
Join us for an unforgettable night to defeat ovarian cancer. Female chefs, mixologists and restaurat...May 8 @ 6:30 pm - 8:30 pm EDT